Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Medrysone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 8/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.71 |
| ▸ | HSD11B2 | P80365 | 3/20 | 0.70 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.70 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | SHBG | P04278 | 3/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Medrysone SCHEMBL13054978 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2HIF1ACYP2C9LMNA | |
| Medrysone SCHEMBL4493 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2HIF1ACYP2C9LMNA | |
| Medrysone SCHEMBL29866793 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2HIF1ACYP2C9LMNA | |
| Medrysone SCHEMBL12998543 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2HIF1ACYP2C9LMNA | |
| Medrysone SCHEMBL840781 | 0.96 | CYP3A4 (0.93) | CYP3A4SMN1; SMN2HIF1ACYP2C9LMNA | |
| SCHEMBL23975165 | 0.92 | CYP3A4 (0.85) | CYP3A4SMN1; SMN2HIF1ACYP2C9LMNA | |
| SCHEMBL8668298 | 0.89 | SMN1; SMN2 (0.80) | CYP3A4SMN1; SMN2HIF1ACYP2C9LMNA | |
| SCHEMBL8668291 | 0.89 | SMN1; SMN2 (0.80) | CYP3A4SMN1; SMN2HIF1ACYP2C9LMNA | |
| SCHEMBL6018287 | 0.87 | CYP3A4 (0.77) | CYP3A4SMN1; SMN2HIF1ACYP2C9LMNA | |
| SCHEMBL6018282 | 0.87 | CYP3A4 (0.77) | CYP3A4SMN1; SMN2HIF1ACYP2C9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | claimed |
| US-20030092706-A1 | Combination | NYCOMED GMBH (DE) | 2003-05-15 | — | — | US | claimed |
| US-20100028360-A1 | METHODS FOR THE MODULATION OF BRAIN PROGESTAGEN SIGNALING IN THE PREVENTION AND TREATMENT OF NEUROLOGICAL DISORDERS AND NEURODEGENERATIVE DISEASES | ATWOOD CRAIG STEPHEN | 2010-02-04 | — | — | US | disclosed |
| US-20070270441-A1 | Combination | ALTANA PHARMA AG (DE) | 2007-11-22 | — | — | US | disclosed |
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | disclosed |
| EP-1412346-B1 | METHOD FOR PRODUCING NOVEL SPINOSYN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2005-03-09 | — | — | EP | disclosed |
| EP-1448202-A1 | COMBINATION OF A PDE4 OR PDE3/4 INHIBITOR AND AN ANTI-RHEUMATIC DRUG | ALTANA Pharma AG (DE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003039552-A1 | COMBINATION OF PDE4 OR PDE3/4 INHIBITOR AND AN ANTI-RHEUMATIC DRUG | ALTANA PHARMA AG (DE) | 2003-05-15 | — | — | WO | disclosed |
| US-20030092706-A1 | Combination | NYCOMED GMBH (DE) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | RECQL, GSS, DDX17 | NR3C1 104/4885CYP3A4 2529/4885SMN1; SMN2 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.